EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS.

Q3 Medicine

Experimental oncology Pub Date : 2022-05-01 DOI:10.32471/exp-oncology.2312-8852.vol-44-no-1.17496

Z. Moghaddam, Mina Rostami, A. Zeraatchi, H. Abadi, Farzaneh Karamitanha, Hamidreza Amirmoghaddami

{"title":"EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS.","authors":"Z. Moghaddam, Mina Rostami, A. Zeraatchi, H. Abadi, Farzaneh Karamitanha, Hamidreza Amirmoghaddami","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-1.17496","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nSide effects of chemotherapy in cancer patients need to be investigated in more detail.\n\n\nAIM\nTo determine the incidence of cardiotoxicity in patients treated with different chemotherapy regimens containing 5-fluorouracil (5-FU) in Zanjan, Iran.\n\n\nPATIENTS AND METHODS\nIn a prospective cohort study, patients with different types of solid gastrointestinal tumors who were candidates for 5-FU based chemotherapy regimens were enrolled. The study population consisted of 100 patients (48 females and 52 males) with a mean age of 63.99 ± 12.40 years. We measured serum cardiac troponin I (cTnI) levels before and during each chemotherapy cycle and determined the occurrence of cardiotoxicity in patients based on the levels of cTnI, clinical signs and symptoms as well as electrocardiogram findings. In addition, we assessed a history of diabetes, hypertension, smoking, dyslipidemia and previous chest radiation as potential risk factors for cardiotoxicity.\n\n\nRESULTS\nThe incidence of cardiotoxicity was 8%, of which 5 patients were diagnosed with acute coronary syndrome, 2 patients with arrhythmias and one with hypotension. In addition, there was no significant association between studied risk factors and 5-FU induced cardiotoxicity.\n\n\nCONCLUSION\nThe incidence of cardiotoxicity in patients receiving 5-FU infusion regimens was notable. Thus, paying more attention to the 5-FU-induced cardiotoxicity is necessary in order to improve the prognosis of patients with cancer.","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 1 1","pages":"60-66"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-1.17496","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

BACKGROUND Side effects of chemotherapy in cancer patients need to be investigated in more detail. AIM To determine the incidence of cardiotoxicity in patients treated with different chemotherapy regimens containing 5-fluorouracil (5-FU) in Zanjan, Iran. PATIENTS AND METHODS In a prospective cohort study, patients with different types of solid gastrointestinal tumors who were candidates for 5-FU based chemotherapy regimens were enrolled. The study population consisted of 100 patients (48 females and 52 males) with a mean age of 63.99 ± 12.40 years. We measured serum cardiac troponin I (cTnI) levels before and during each chemotherapy cycle and determined the occurrence of cardiotoxicity in patients based on the levels of cTnI, clinical signs and symptoms as well as electrocardiogram findings. In addition, we assessed a history of diabetes, hypertension, smoking, dyslipidemia and previous chest radiation as potential risk factors for cardiotoxicity. RESULTS The incidence of cardiotoxicity was 8%, of which 5 patients were diagnosed with acute coronary syndrome, 2 patients with arrhythmias and one with hypotension. In addition, there was no significant association between studied risk factors and 5-FU induced cardiotoxicity. CONCLUSION The incidence of cardiotoxicity in patients receiving 5-FU infusion regimens was notable. Thus, paying more attention to the 5-FU-induced cardiotoxicity is necessary in order to improve the prognosis of patients with cancer.

查看原文本刊更多论文

评估5-氟尿嘧啶诱导的心脏毒性:心脏生物标志物的作用。

背景癌症患者化疗的副作用需要更详细的研究。目的确定在伊朗赞詹接受不同含5-氟尿嘧啶（5-FU）化疗方案的患者的心脏毒性发生率。研究对象和方法在一项前瞻性队列研究中，纳入了不同类型的胃肠道实体瘤患者，这些患者是基于5-FU的化疗方案的候选者。研究人群包括100名患者（48名女性和52名男性），平均年龄为63.99±12.40岁。我们在每个化疗周期之前和期间测量了血清肌钙蛋白I（cTnI）水平，并根据cTnI水平、临床体征和症状以及心电图结果确定了患者心脏毒性的发生。此外，我们评估了糖尿病、高血压、吸烟、血脂异常和既往胸部辐射史是心脏毒性的潜在危险因素。结果心脏毒性发生率为8%，其中5例诊断为急性冠状动脉综合征，2例诊断为心律失常，1例诊断为低血压。此外，所研究的危险因素与5-FU诱导的心脏毒性之间没有显著关联。结论5-FU输注方案的心脏毒性发生率显著。因此，为了改善癌症患者的预后，有必要更多地关注5-FU诱导的心脏毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental oncology Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.